Jia Liu – CEO, DreamCIS, South Korea
Jia Liu, CEO of DreamCIS, a Korean CRO, part of the Chinese company Tigermed, talks about her vision for DreamCIS to be “the CRO everybody wants to work with”. Liu…
Address: 1010, 10F, Jeokseon Hyundai Bld, 80, Jeokseon-dong, Seoul, Jongno-gu, Seoul,Republic of Korea
Tel: +82 2 2010 4500
DreamCIS is a full service contract research organization (CRO) that offers to the pharmaceutical companies, bio venture companies, medical device manufacturers, and functional food producers. DreamCIS provides clinical trial services for a broad and detailed range of therapeutic area in accordance with the standard operating procedures consistent with both Republic of Korean regulations and global standards including ICH-GCP guidelines. DreamCIS aims at enhancing both the reliability of its clinical services provided and product competitiveness by striving to maintain the consistency in quality of its services. Accomplishing this goal will no doubt enable us to contribute to the health of the people. DreamCIS has its Specialist Advisory Committee comprised of high-level specialists in their field to provide comprehensive and specialized clinical services. The community in partnership with DreamCIS include Ionet Republic of Korea which was organized by DreamCIS exclusively for the development of Web-CRF program, DreamCIS’s patented product, Yonsei University Department of Biostatics Medical College, YOU & ME Patent and Law Firm, Yonsei University Research Institute of Food & Nutrition, SMSI (Seoul Medical Science Institute), Biotoxtech Co.,Ltd. DreamCIS has launched a business partnership with Gleneagles CRC (Singapore), a leading CRO/SMO in the Asia Pacific region, with the aim to conduct multi-national clinical trials seamlessly for multi-national customers as well. Founded in April, 2000, DreamCIS has ever since been dedicated to providing a full range of clinical services for a number of customers/sponsors, including major pharmaceutical companies, multi-national pharmaceutical companies, bio venture companies, health food producers, and medical device manufacturers in Republic of Korea. DreamCIS will continue striving to provide customers reliable clinical trial data while conducting all of clinical trials using our expertise and significant experience in the field of clinical trials.
It aims to provide customers differentiated services based on strict quality control in a scientific and systematic manner and high ethical standards. DreamCIS’ key service areas include: ㆍClinical trials for medicines / medical devices ㆍPost-marketing surveillance (PMS) ㆍQA audit ㆍData management and Statistical analysis ㆍHealth functional foods Trials ㆍPre-clinical trials management ㆍTraining and dispatch of clinical research nurses
Jia Liu, CEO of DreamCIS, a Korean CRO, part of the Chinese company Tigermed, talks about her vision for DreamCIS to be “the CRO everybody wants to work with”. Liu…
A roundup of some of the biggest stories from South Korean healthcare and pharma, including the government’s continuing standoff with doctors over medical reform plans; Merck’s plans for a new…
Despite its ageing population and growing need for healthcare, South Korea had just 2.6 doctors per 1,000 inhabitants in 2022, one of the lowest numbers among developed nations. To deal…
The latest pharma and healthcare news from APAC, including Celltrion’s plans to sell its Takeda portfolio to CBC; reforms to the South Korean national insurance system that may lead to…
Global medtech giant Medtronic is hoping that its latest acquisition – EOFlow, a South Korean wearable insulin patch maker – will enhance its competitiveness in the global diabetes market. …
A roundup of some of the most important recent stories from the burgeoning South Korean pharma and biotech industry, including a government plan to expand collaboration with the global innovation…
As big pharma continues to sharpen its focus on R&D by outsourcing other elements of the supply chain, including manufacturing, CDMOs have thrived. Samsung Biologics, one of the world’s top…
After launching the first Korean COVID-19 vaccine, SKYCovione, SK Bioscience is preparing for its next big milestone, a US subsidiary, with the appointment of two new executives who are already…
SK Bioscience’s announcement that the first batch of its domestically developed COVID vaccine has been shipped may mark a significant milestone in South Korea’s journey towards greater vaccine self-sufficiency. …
ExoCoBio’s CEO, Byong Seung Cho, went from biotech venture capital to setting up ExoCoBio, a company whose core technology is based on adipose stem-cell derived exosomes for regenerative medicine and…
South Korea has carved a place for itself as a dominant player in the global pharma and med-tech manufacturing industry with national companies Samsung Biologics and Celltrion leading the way.…
After a dynamic two years as CEO of Samsung Biologics, John Rim highlights some of the fundamentals behind the company’s rapid growth as a CDMO, including the creation of huge…
Stephen Yoo highlights the pioneering work that STCube Pharmaceuticals – a US subsidiary of Korean firm STCube – is undertaking in the immuno-oncology field, its three technology platforms, partnership approach,…
See our Cookie Privacy Policy Here
